New hope to tame the storm: drug trial aims to shield patients from CAR-T's worst side effects
NCT ID NCT04148430
Summary
This study is testing if a drug called anakinra can prevent or reduce severe brain-related side effects and dangerous immune reactions in adults receiving CAR-T cell therapy for certain B-cell cancers. The goal is to make this powerful cancer treatment safer by controlling its most serious complications. Researchers are enrolling 62 adults who have relapsed B-cell leukemia or lymphoma and are scheduled to get approved CAR-T therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hackensack Meridian Health (Data collection only)
Hackensack, New Jersey, 07601, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.